Executive Summary
Azoth Analytics has released a research report titled "Global IgG Mediated Autoimmune Diseases Biologic Drugs Market (2024 Edition)" which provides a complete analysis of the Global IgG Mediated Autoimmune Diseases Biologic Drugs industry in terms of market segmentation By Antibody Source (Humanized, Fully Human, Chimeric, Other Antibody Sources), By Indication (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Other Indications) for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.
The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, South India). The Global IgG Mediated Autoimmune Diseases Biologic Drugs market showcased growth at a CAGR of 7.25% during 2019-2022. The market was valued at USD 123.99 Billion in 2022 which is expected to reach USD 197.78 Billion in 2029. The increasing incidence and prevalence of IgG mediated autoimmune diseases such as rheumatoid arthritis, lupus, and psoriasis are major drivers for the growth of biologic drugs.
Factors such as genetic predisposition, environmental triggers, and lifestyle changes contribute to the rising burden of autoimmune diseases globally. Additionally, The aging population worldwide is more susceptible to autoimmune diseases, driving the demand for biologic drugs. Elderly individuals often experience multiple comorbidities and may require more targeted and effective treatments, contributing to the expansion of the biologic drugs market.
Biologic drugs for IgG mediated autoimmune diseases represent a significant advancement in medical treatment, as they are meticulously engineered to selectively target key components of the immune system implicated in the pathogenesis of these diseases. This precision targeting distinguishes them from conventional treatments, which often have broader mechanisms of action and can lead to more generalized effects.
For instance, these biologic drugs may directly inhibit certain pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) or interleukins (ILs), which play crucial roles in promoting inflammation and tissue damage in autoimmune conditions like rheumatoid arthritis or inflammatory bowel disease. By specifically targeting these cytokines, biologic therapies can disrupt the inflammatory cascade at its source, thereby alleviating symptoms and preventing disease progression more effectively than traditional therapies.
The global market for IgG mediated autoimmune diseases biologic drugs is highly competitive, with numerous pharmaceutical companies and biotechnology firms competing for market share.
Scope of the Report
• The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market by Value (USD Billion).
• The report presents the analysis of IgG Mediated Autoimmune Diseases Biologic Drugs Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
• The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market By Antibody Source (Humanized, Fully Human, Chimeric, Other Antibody Sources)
• The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market By Indication (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Other Indications).
• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Antibody Sources, by mode of operation & by end users.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Johnson & Johnson, Pfizer, Novartis AG, Roche Holding AG, Eli Lilly and Company, Abbvie Inc., Sanofi, GSK plc., and UCB S.A
Azoth Analytics has released a research report titled "Global Simulation and Analysis Market (2024 Edition)" which provides a complete analysis of the Global Simulation and Analysis Market industry in terms of market segmentation By Component (Software, Service) Deployment (On-premise, Cloud) and End-use (Automotive, Aerospace & Defense, Industrial Manufacturing, Healthcare, Others). The report analyzes the Global Simulation and Analysis Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
The report analyses the Simulation and Analysis Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Brazil, Germany, United Kingdom, France, China, Japan, South Korea, India). The research study also assesses growth indicators, restraints, sales growth and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market's evolution.
During the forecast period, 2024-2029, the Global Simulation and Analysis Market is expected to expand at a CAGR of 8.6%. The global Simulation and Analysis market is expected to grow at an extraordinary rate driven by the significant adoption of simulation tools from key players. The Global Simulation and Analysis market is expected to increase from USD 10.26 billion in 2024 to USD 15.50 billion in 2029, according to Azoth Analytics' estimates. The significance of simulation tools has increased with the advent of the Fourth Industrial Revolution, which is marked by smart manufacturing and networking. With significant market value, the global simulation and analysis market is a dynamic, growing business. It covers a wide range of industries, such as aerospace, automotive, manufacturing, and healthcare. The growing utilization of simulation software in various sectors for process optimization, product development, and operational efficiency is the primary factor driving the market value.
The increasing demand for virtual testing and training solutions, technical improvements, and the integration of simulation across many industries are driving considerable growth in the global simulation and analysis market. Simulation and analysis solutions are being used more and more in a variety of industries, such as aerospace, automotive, healthcare, manufacturing, and defence, for testing, product development, training, and operational optimization.
Growing Advancements in Simulation Software
The rapid development of technology has led to the emergence of increasingly complex and functional simulators that provide improved performance and capabilities. These developments allow companies in a range of industries to run more detailed and lifelike simulations, more accurately simulating complicated real-world situations. The development of simulation software has increased the precision of virtual models and broadened the industries and applications in which they can be used successfully.
Furthermore, as simulation software becomes more sophisticated, manufacturing, product development, and other crucial activities become more productive and efficient. Predictive modelling, optimization, and scenario analysis are made possible by the powerful algorithms, artificial intelligence, and machine learning included in modern simulation programs. The development of simulation software is a strong option for enterprises looking to improve decision-making, reduce expenses, and streamline processes. As more sectors come to understand the importance of these advanced methods in accomplishing their goals, the Simulation and Analysis Market is expected to grow as a result of these tools, which enable organizations to make better decisions, generate innovation, and obtain deeper insights.
Complexity and Integration Issues
The complexity and concerns with integration related to simulation and analysis tools pose significant barriers to the expansion of the worldwide market. The complex nature of these innovative tools, which frequently call for specific knowledge for efficient implementation and use, is one of the main challenges. It can be difficult to integrate simulation software into current workflows and systems, which might cause problems with older systems. Enterprises may encounter challenges in ensuring seamless interaction among diverse simulation tools and systems, hindering the general effectiveness and convenience of these technologies. User-friendly interfaces and seamless integration are becoming essential as industries want to exploit simulation's advantages for better decision-making and efficiency. For simulation and analytic solutions to be widely adopted and for companies to fully benefit from the insights and optimizations these tools can provide across a variety of sectors, these complexity and integration issues must be resolved.
Scope of the Report
• The report analyses the Global Simulation and Analysis Market by Value (USD Billion).
• The report presents the analysis of the Global Simulation and Analysis Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
• The report analyses the Global Simulation and Analysis Market by Component (Software, Service).
• The report analyses the Simulation and Analysis Market by Deployment (On-premise, Cloud).
• The report analyses the Simulation and Analysis Market by End-use (Automotive, Aerospace & Defense, Industrial Manufacturing, Healthcare, Others).
• The report analyses the Simulation and Analysis Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa).
• The report analyses the Simulation and Analysis Market by Country (United States, Canada, Brazil, Germany, United Kingdom, France, China, Japan, South Korea, India).
• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis.
• Also, the major opportunities, trends, drivers and challenges of the industry have been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Altair Engineering Inc., Ansys, Inc., Autodesk, Inc., Dassault Systemes, Certara, Inc., Hexagon AB, Keysight Technologies, Simulations Plus, Inc., Gamma Technologies and Siemens Digital Industries Software.
Table of Content
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
2. Analyst Recommendations
2.1 Shift towards targeted therapies and personalized medicine
2.2 Adoption of biosimilars and biobetters
3. Global IgG-mediated Autoimmune Disease Biologic Drugs Market: Historic and Forecast
3.1 Impact Analysis of Macro Economic Factors on Global IgG-mediated Autoimmune Disease Biologic Drugs Market
3.2 Biologics in Pipeline for Rheumatoid Arthritis
3.3 Biologics in Pipeline for Multiple Sclerosis
3.4 Biologics in Pipeline for Systemic Lupus Erythematosus
3.5 Ten top-selling antibodies globally, 2019
3.6 Global IgG-mediated Autoimmune Disease Biologic Drugs Market: Dashboard
3.7 Global IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
3.8 Global IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Value Assessment
3.9 Assessment Degree of Impact of COVID-19 on Global IgG-mediated Autoimmune Disease Biologic Drugs Market
3.10 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Antibody Source
3.10.1 Global IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source Overview
3.10.2 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Attractiveness Index, By Antibody Source
3.10.3 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)
3.10.4 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)
3.10.5 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Chimeric, By Value, 2019H-2029F (USD Billion & CAGR)
3.10.6 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Antibody Sources, By Value, 2019H-2029F (USD Billion & CAGR)
3.11 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Indication
3.11.1 Global IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication Overview
3.11.2 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Attractiveness Index, By Indication
3.11.2 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Billion & CAGR)
3.11.3 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Billion & CAGR)
3.11.4 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Multiple Sclerosis, By Value, 2019H-2029F (USD Billion & CAGR)
3.11.5 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
4 IgG-mediated Autoimmune Disease Biologic Drugs Market, Region Analysis
4.1 Regional Coverage of the Study
4.2 Regional Snapshot
5 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market: Historic and Forecast
5.1 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market: Snapshot
5.2 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
5.3 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market: Key Factors
5.4 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market: Segment Analysis
5.5 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Antibody Source
5.5.1 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source Overview
5.5.2 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)
5.5.3 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)
5.5.4 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Chimeric, By Value, 2019H-2029F (USD Billion & CAGR)
5.5.5 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Antibody Sources, By Value, 2019H-2029F (USD Billion & CAGR)
5.6 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Indication
5.6.1 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication Overview
5.6.2 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Billion & CAGR)
5.6.3 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Billion & CAGR)
5.6.4 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Multiple Sclerosis, By Value, 2019H-2029F (USD Billion & CAGR)
5.6.5 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
5.7 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Country
5.7.1 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, by Country Overview
5.7.2 United States IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
5.7.2.1 United States IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
5.7.2.2 United States IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
5.7.3 Canada IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
5.7.3.1 Canada IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
5.7.3.2 Canada IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
5.7.4 Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
5.7.5.1 Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
5.7.5.2 Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
6. Europe IgG-mediated Autoimmune Disease Biologic Drugs Market: Historic and Forecast
6.1 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market: Snapshot
6.2 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.3 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market: Key Factors
6.4 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market: Segment Analysis
6.5 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Antibody Source
6.5.1 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source Overview
6.5.2 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)
6.5.3 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)
6.5.4 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Chimeric, By Value, 2019H-2029F (USD Billion & CAGR)
6.5.5 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Antibody Sources, By Value, 2019H-2029F (USD Billion & CAGR)
6.6 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Indication
6.6.1 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication Overview
6.6.2 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Billion & CAGR)
6.6.3 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Billion & CAGR)
6.6.4 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Multiple Sclerosis, By Value, 2019H-2029F (USD Billion & CAGR)
6.6.5 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
6.7 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Country
6.7.1 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, by Country Overview
6.7.2 United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.7.2.1 United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
6.7.2.2 United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
6.7.3 Germany IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.7.3.1 Germany IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
6.7.3.2 Germany IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
6.7.4 France IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.7.4.1 France IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
6.7.4.2 France IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
6.7.5 Italy IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.7.5.1 Italy IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
6.7.5.2 Italy IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
6.7.6 Spain IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.7.6.1 Spain IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
6.7.6.2 Spain IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
6.7.6 Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.7.6.1 Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
6.7.6.2 Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
7. Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market: Historic and Forecast
7.1 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market: Snapshot
7.2 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.3 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market: Key Factors
7.4 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market: Segment Analysis
7.5 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Antibody Source
7.5.1 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source Overview
7.5.2 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)
7.5.3 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)
7.5.4 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Chimeric, By Value, 2019H-2029F (USD Billion & CAGR)
7.5.5 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Antibody Sources, By Value, 2019H-2029F (USD Billion & CAGR)
7.6 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Indication
7.6.1 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication Overview
7.6.2 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Billion & CAGR)
7.6.3 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Billion & CAGR)
7.6.4 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Multiple Sclerosis, By Value, 2019H-2029F (USD Billion & CAGR)
7.6.5 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
7.7 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Country
7.7.1 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, by Country Overview
7.7.2 China IgG-mediated Autoimmune Disease Biologic Drugs Market : Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.7.2.1 China IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
7.7.2.2 China IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
7.7.3 Japan IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.7.3.1 Japan IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
7.7.3.2 Japan IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
7.7.4 India IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.7.4.1 India IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
7.7.4.2 India IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
7.7.5 Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.7.5.1 Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
7.7.5.2 Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
8. Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market: Historic and Forecast
8.1 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market: Snapshot
8.2 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
8.3 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market: Key Factors
8.4 Middle East and Africa IgG-mediated Autoimmune Disease Biologic Drugs Market: Segment Analysis
8.5 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Antibody Source
8.5.1 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source Overview
8.5.2 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)
8.5.3 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)
8.5.3 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Chimeric, By Value, 2019H-2029F (USD Billion & CAGR)
8.5.5 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Antibody Sources By Value, 2019H-2029F (USD Billion & CAGR)
8.6 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Indication
8.6.1 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication Overview
8.6.2 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Billion & CAGR)
8.6.3 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Billion & CAGR)
8.6.4 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Multiple Sclerosis, By Value, 2019H-2029F (USD Billion & CAGR)
8.6.5 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
9. Market Dynamics
9.1 Impact assessment of Market Dynamics on IgG-mediated Autoimmune Disease Biologic Drugs Market
9.2 Drivers
9.3 Restraints
9.4 Trends
10. Industry Ecosystem Analysis
10.1 Porter Analysis
11. Competitive Positioning
11.1 Companies' Product Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of IgG-mediated Autoimmune Disease Biologic Drugs Market
11.4 Company Profiles
11.4.1 Johnson & Johnson
11.4.2 Pfizer
11.4.3 Novartis AG
11.4.4 Roche Holding AG
11.4.5 Eli Lilly and Company
11.4.6 Abbvie Inc.
11.4.7 Sanofi
11.4.8 GSK plc.
11.4.9 UCB S.A
12. About Us & Disclaimer
Request Sample 
Request Discount 
Inquire Before Buy
